FUSN Fusion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FUSN

Price (delayed)

$21.45

Market cap

$1.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.45

Enterprise value

$1.8B

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the ...

Highlights
Fusion Pharmaceuticals's equity has increased by 37% YoY and by 18% QoQ
The quick ratio has grown by 31% since the previous quarter and by 27% year-on-year
The gross profit has grown by 42% YoY but it has contracted by 6% from the previous quarter
FUSN's revenue is up by 42% YoY but it is down by 6% QoQ
Fusion Pharmaceuticals's net income has decreased by 8% YoY and by 3.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://fusionpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FUSN
Market
Shares outstanding
84.69M
Market cap
$1.82B
Enterprise value
$1.8B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.98
Price to sales (P/S)
680.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
872.44
Earnings
Revenue
$2.07M
EBIT
-$88.94M
EBITDA
-$85.08M
Free cash flow
-$85.69M
Per share
EPS
-$1.45
Free cash flow per share
-$1.31
Book value per share
$3.07
Revenue per share
$0.03
TBVPS
$4.36
Balance sheet
Total assets
$285.84M
Total liabilities
$63.36M
Debt
$50.33M
Equity
$222.48M
Working capital
$227.18M
Liquidity
Debt to equity
0.23
Current ratio
15.01
Quick ratio
14.48
Net debt/EBITDA
0.15
Margins
EBITDA margin
-4,114.1%
Gross margin
100%
Net margin
-4,588.8%
Operating margin
-4,798.5%
Efficiency
Return on assets
-35.3%
Return on equity
-46.6%
Return on invested capital
-34.5%
Return on capital employed
-33%
Return on sales
-4,301%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FUSN stock price

How has the Fusion Pharmaceuticals stock price performed over time
Intraday
-0.19%
1 week
0.14%
1 month
0.52%
1 year
424.45%
YTD
123.2%
QTD
0.61%

Financial performance

How have Fusion Pharmaceuticals's revenue and profit performed over time
Revenue
$2.07M
Gross profit
$2.07M
Operating income
-$99.23M
Net income
-$94.9M
Gross margin
100%
Net margin
-4,588.8%
The gross profit has grown by 42% YoY but it has contracted by 6% from the previous quarter
FUSN's revenue is up by 42% YoY but it is down by 6% QoQ
Fusion Pharmaceuticals's net margin has increased by 23% YoY but it has decreased by 11% from the previous quarter
Fusion Pharmaceuticals's operating margin has increased by 20% YoY but it has decreased by 11% from the previous quarter

Growth

What is Fusion Pharmaceuticals's growth rate over time

Valuation

What is Fusion Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.98
P/S
680.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
872.44
The EPS has grown by 28% YoY and by 11% from the previous quarter
Fusion Pharmaceuticals's equity has increased by 37% YoY and by 18% QoQ
The P/S is 88% above the last 4 quarters average of 362.9
FUSN's revenue is up by 42% YoY but it is down by 6% QoQ

Efficiency

How efficient is Fusion Pharmaceuticals business performance
The return on invested capital has increased by 31% year-on-year and by 3.9% since the previous quarter
The ROS has grown by 28% YoY but it has contracted by 9% from the previous quarter
FUSN's ROA is up by 7% YoY and by 2.8% QoQ
FUSN's return on equity is up by 3.7% since the previous quarter

Dividends

What is FUSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FUSN.

Financial health

How did Fusion Pharmaceuticals financials performed over time
The quick ratio has grown by 31% since the previous quarter and by 27% year-on-year
FUSN's total assets is up by 30% year-on-year and by 13% since the previous quarter
Fusion Pharmaceuticals's debt is 77% less than its equity
Fusion Pharmaceuticals's equity has increased by 37% YoY and by 18% QoQ
Fusion Pharmaceuticals's debt has increased by 25% YoY but it has decreased by 4.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.